Floatz logo

Kln-1010

Hemostatic Disorders

Kelonia Therapeutics, Inc.gene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hemostatic Disorders cohort.

Asset / SponsorPhaseRating
Oricar-017
OriCell Therapeutics Co., Ltd.
Phase 1CC
Cynk-001
Celularity Incorporated
Phase 1D
HUMAN ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX
Assiut University
D
Tranexamic Acid
Assiut University
D

Same molecule, other indications

Kln-1010 is also rated in:

neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
vascular disorderDormant
CC
Indicative ·
43 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →